Premium
Prognostic factors from a randomized clinical trial in resected lung cancer
Author(s) -
Chastang Claude,
Lebeau Bernard,
Charpak Yves,
Decroix Guy
Publication year - 1985
Publication title -
statistics in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.996
H-Index - 183
eISSN - 1097-0258
pISSN - 0277-6715
DOI - 10.1002/sim.4780040306
Subject(s) - randomized controlled trial , medicine , lung cancer , stage (stratigraphy) , disease , oncology , clinical trial , immunotherapy , cancer , paleontology , biology
Prognostic information has three main uses: prediction of the course of evolution of disease, decisions about treatment and limitation of complementary tests. Using data from a randomized controlled clinical trial of immunotherapy in resected lung cancer, we identified factors of prognostic importance. In particular we demonstrated that a time‐consuming and expensive cell‐mediated immunity test is not of prognostic value. Our cooperative group decided to cancel this test in the routine examination of patients with resected lung cancer. Disease stage was confirmed as the main prognostic factor.